Nanopharmaceuticals for wound healing - Lost in translation?

被引：69

作者：

Ashtikar, Mukul

Wacker, Matthias G.

机构：

[1] Fraunhofer Inst Mol Biol & Appl Ecol IME, Dept Pharmaceut Technol & Nanosci, Frankfurt, Germany

[2] Goethe Univ, Inst Pharmaceut Technol, Frankfurt, Germany

来源：

ADVANCED DRUG DELIVERY REVIEWS | 2018年 / 129卷

关键词：

Nanomaterials; Biomaterials; Advanced wound healing therapies; Current regulatory perspective; ENDOTHELIAL GROWTH-FACTOR; DIABETIC FOOT ULCERS; NANOCRYSTALLINE SILVER DRESSINGS; CONTROLLED DRUG-RELEASE; MARINE SPONGE COLLAGEN; BLOOD-BRAIN-BARRIER; IN-VITRO; POLY(ETHYLENE GLYCOL); HYALURONIC-ACID; HUMAN SKIN;

D O I：

10.1016/j.addr.2018.03.005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Today, many of the newly developed pharmaceuticals and medical devices take advantage of nanotechnology and with a rising incidence of chronic diseases such as diabetes and cardiovascular disease, the number of patients afflicted globally with non-healing wounds is growing. This has created a requirement for improved therapies and wound care. However, converting the strategies applied in early research into new products is still challenging. Many of them fail to comply with the market requirements. This review discusses the legal and scientific challenges in the design of nanomedicines for wound healing. Are they lost in translation or is there a new generation of therapeutics in the pipeline? (C) 2018 Elsevier B.V. All rights reserved.

引用

页码：194 / 218

页数：25

共 326 条

[1]

A. International, 2010, STAND SPEC AM POL LA

[2] Standardized in vitro drug release test for colloidal drug carriers using modified USP dissolution apparatus I [J].